Ginkgo Bioworks Holdings annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Ginkgo Bioworks Holdings R&D Spending Growth & History (DNA)
Ginkgo Bioworks Holdings's r&d spending was $243.8M for fiscal 2025.
View full Ginkgo Bioworks Holdings company overviewGinkgo Bioworks Holdings annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $243.8M | −$180.3M | −42.51% |
| 2024 | 2024-12-31 | $424.1M | −$156.6M | −26.96% |
| 2023 | 2023-12-31 | $580.6M | −$472.0M | −44.84% |
| 2022 | 2022-12-31 | $1.05B | −$97.0M | −8.44% |
| 2021 | 2021-12-31 | $1.15B | $989.9M | +619.59% |
| 2020 | 2020-12-31 | $159.8M | $63.5M | +65.91% |
| 2019 | 2019-12-31 | $96.3M | — | — |
Ginkgo Bioworks Holdings quarterly r&d spending
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $46.2M | −$7.2M | −13.42% |
| Q1 2026 | 2026-03-31 | $49.9M | −$21.0M | −29.61% |
| Q4 2025 | 2025-12-31 | $50.1M | −$26.3M | −34.37% |
| Q3 2025 | 2025-09-30 | $69.4M | −$7.7M | −9.94% |
| Q2 2025 | 2025-06-30 | $53.4M | −$80.9M | −60.24% |
| Q1 2025 | 2025-03-31 | $70.9M | −$65.5M | −48.03% |
| Q4 2024 | 2024-12-31 | $76.4M | −$40.7M | −34.74% |
| Q3 2024 | 2024-09-30 | $77.0M | −$79.7M | −50.85% |
| Q2 2024 | 2024-06-30 | $134.2M | −$10.1M | −6.97% |
| Q1 2024 | 2024-03-31 | $136.5M | −$26.2M | −16.10% |
| Q4 2023 | 2023-12-31 | $117.0M | −$60.5M | −34.08% |
| Q3 2023 | 2023-09-30 | $156.7M | −$104.8M | −40.08% |
| Q2 2023 | 2023-06-30 | $144.3M | −$145.8M | −50.26% |
| Q1 2023 | 2023-03-31 | $162.6M | −$160.9M | −49.74% |
| Q4 2022 | 2022-12-31 | $177.5M | −$807.5M | −81.98% |
| Q3 2022 | 2022-09-30 | $261.5M | $208.4M | +393.13% |
| Q2 2022 | 2022-06-30 | $290.1M | $238.0M | +457.47% |
| Q1 2022 | 2022-03-31 | $323.6M | $264.0M | +443.05% |
| Q4 2021 | 2021-12-31 | $985.0M | — | — |
| Q3 2021 | 2021-09-30 | $53.0M | $17.0M | +46.99% |
| Q2 2021 | 2021-06-30 | $52.0M | — | — |
| Q1 2021 | 2021-03-31 | $59.6M | — | — |
| Q3 2020 | 2020-09-30 | $36.1M | — | — |
Ginkgo Bioworks Holdings r&d spending trends
Over the last five fiscal years, Ginkgo Bioworks Holdings's r&d spending increased from $159.8M to $243.8M, a change of $84.0M. The latest reported quarter, Q2 2026, shows $46.2M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ginkgo Bioworks Holdings source filings ↗Community posts
Ginkgo joins a federally backed RNA-manufacturing project worth up to $17.5 million
Ginkgo Bioworks ($DNA) received a subcontract worth up to $17.5 million to participate in an ARPA-H program focused on RNA manufacturing. Waterfall Scientific is the prime contractor. The project, called ESCALATOR, is intended to combine co ...